Tags

Type your tag names separated by a space and hit enter

Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease.
Mov Disord. 2006 Jul; 21(7):983-8.MD

Abstract

The aim of this research was to quantify sleep problems in patients suffering from Parkinson's disease by means of the new Parkinson's Disease Sleep Scale (PDSS) and to correlate such problems with the possible influence of current drug treatment. A total of 70 patients (36 men and 34 women) with a diagnosis of Parkinson's disease were enrolled. Their mean age was 69.7 +/- 8.2 years, and duration of disease was 7.4 +/- 4.8 years. All patients completed the PDSS and the Unified Parkinson's Disease Rating Scale (UPDRS Parts I-IV). Drug consumption and doses were registered. The mean score on the PDSS scale was 109.23 +/- 19.75 and on the UPDRS III scale was 25.24 +/- 11.35. The lowest scores were obtained in Item 3 (sleep fragmentation): 5.53 (2.46); and in Item 8 (nocturia): 5.75 (2.91). There was a weak correlation between the PDSS and UPDRS III (cc = -0.355, P = 0.003), PDSS and UPDRS I (cc = -0.272, P = 0.02), and PDSS and UPDRS IV (cc = -0.416, P < 0.001). Motor conditions, mental state, and drug complications influence sleep quality. Although this effect was significant, it was not of a great magnitude. Dopaminergic drugs did not increase daytime sleepiness. As a whole, sleep quality in patients who took dopaminergic agonists did not differ from that of patients who took levodopa in monotherapy.

Authors+Show Affiliations

Neurology Service, Movement Disorders Unit, Cruces Hospital, Baracaldo, and Neurosciences Department, University of the Basque Country, Vizcaya, Spain. jgomeze@meditex.esNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16602112

Citation

Gómez-Esteban, Juan Carlos, et al. "Sleep Complaints and Their Relation With Drug Treatment in Patients Suffering From Parkinson's Disease." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 21, no. 7, 2006, pp. 983-8.
Gómez-Esteban JC, Zarranz JJ, Lezcano E, et al. Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease. Mov Disord. 2006;21(7):983-8.
Gómez-Esteban, J. C., Zarranz, J. J., Lezcano, E., Velasco, F., Ciordia, R., Rouco, I., Losada, J., & Bilbao, I. (2006). Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society, 21(7), 983-8.
Gómez-Esteban JC, et al. Sleep Complaints and Their Relation With Drug Treatment in Patients Suffering From Parkinson's Disease. Mov Disord. 2006;21(7):983-8. PubMed PMID: 16602112.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease. AU - Gómez-Esteban,Juan Carlos, AU - Zarranz,Juan Jose, AU - Lezcano,Elena, AU - Velasco,Fernando, AU - Ciordia,Roberto, AU - Rouco,Idoia, AU - Losada,Jose, AU - Bilbao,Iker, PY - 2006/4/8/pubmed PY - 2006/12/16/medline PY - 2006/4/8/entrez SP - 983 EP - 8 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 21 IS - 7 N2 - The aim of this research was to quantify sleep problems in patients suffering from Parkinson's disease by means of the new Parkinson's Disease Sleep Scale (PDSS) and to correlate such problems with the possible influence of current drug treatment. A total of 70 patients (36 men and 34 women) with a diagnosis of Parkinson's disease were enrolled. Their mean age was 69.7 +/- 8.2 years, and duration of disease was 7.4 +/- 4.8 years. All patients completed the PDSS and the Unified Parkinson's Disease Rating Scale (UPDRS Parts I-IV). Drug consumption and doses were registered. The mean score on the PDSS scale was 109.23 +/- 19.75 and on the UPDRS III scale was 25.24 +/- 11.35. The lowest scores were obtained in Item 3 (sleep fragmentation): 5.53 (2.46); and in Item 8 (nocturia): 5.75 (2.91). There was a weak correlation between the PDSS and UPDRS III (cc = -0.355, P = 0.003), PDSS and UPDRS I (cc = -0.272, P = 0.02), and PDSS and UPDRS IV (cc = -0.416, P < 0.001). Motor conditions, mental state, and drug complications influence sleep quality. Although this effect was significant, it was not of a great magnitude. Dopaminergic drugs did not increase daytime sleepiness. As a whole, sleep quality in patients who took dopaminergic agonists did not differ from that of patients who took levodopa in monotherapy. SN - 0885-3185 UR - https://www.unboundmedicine.com/medline/citation/16602112/Sleep_complaints_and_their_relation_with_drug_treatment_in_patients_suffering_from_Parkinson's_disease_ L2 - https://doi.org/10.1002/mds.20874 DB - PRIME DP - Unbound Medicine ER -